## Edgar Filing: AVEO PHARMACEUTICALS INC - Form 4

	-	agarrin		011// 01		,						
AVEO PHAF Form 4	RMACEUTICAL	LS INC										
July 02, 2013												
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION									OMB APPROVAL			
Check this box if no longer subject to Section 16. Section 16. Check this box								OMB Number:	3235-0287			
								Expires: January 3 200 Estimated average burden hours per response 0.				
(Print or Type R	esponses)											
WEG KENNETH E Symbol				O PHARMACEUTICALS INC				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
				of Earliest Transaction /Day/Year) /2013				X_ Director 10% Owner Officer (give title Other (specify below) below)				
	(Street) 4. If Amendment, I Filed(Month/Day/Ye				-			<ul><li>6. Individual or Joint/Group Filing(Check</li><li>Applicable Line)</li><li>_X_ Form filed by One Reporting Person</li></ul>				
CAMBRIDO	GE, MA 02139							Form filed by M Person	More than One Re	eporting		
(City)	(State)	(Zip)	Table	e I - Non-D	erivative S	Securi	ties Acc	uired, Disposed o	f, or Beneficial	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any		3. Transactic Code (Instr. 8) Code V	on(A) or Di (D) (Instr. 3,	ispose	d of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
Common Stock	07/01/2013			A <u>(1)</u>	4,541	A	\$ 2.56	47,757	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Unde Secur	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## Edgar Filing: AVEO PHARMACEUTICALS INC - Form 4

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
WEG KENNETH E C/O AVEO PHARMACEUTICALS, INC. 75 SIDNEY STREET CAMBRIDGE, MA 02139	х						
Signatures							
/s/ Joseph D. Vittiglio, attorney-in-fact	07/02/20	13					
<u>**</u> Signature of Reporting Person	Date						

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The transaction reported in this Form 4 was effected pursuant to the reporting person's election on December 5, 2012, in accordance with
   (1) a policy established by the board effective in 2013, to receive 100% of his quarterly installment of board fees in the form of unrestricted shares of the issuer's common stock, issued under the issuer's Amended and Restated 2010 Stock Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.